title: Topical imiquimod therapy for lentigo maligna.
abstract: Lentigo maligna (LM) presents a challenge for complete surgical excision. Imiquimod is a topical immune-response modifier that acts on the immune system. We report our experience using imiquimod 5% cream as a surgical alternative for treatment of LM. Consecutive patients between December 2004 and February 2006 with LM were treated with topical imiquimod. Data on patient and lesion characteristics, side effects of therapy, posttreatment biopsy results, and follow-up was collected. Seven patients were treated with imiquimod 5 nights/wk for 12.4 weeks. Complete histologic and clinical resolution was seen in 86% (6 of 7 patients), at 19.1 months follow-up. Side effects included erythema (86%) and crusting (71%), resulting in dose alteration in 71% of patients. Topical imiquimod therapy demonstrates a high response rate for treatment of LM, with tolerable side effects. Further investigation into its efficacy in the treatment of LM in controlled clinical trials is warranted.
authors.affiliation: Division of Plastic Surgery, University of Toronto, ON, Canada.
authors.forename: Mary-Helen
authors.initials: MH
authors.lastname: Mahoney
authors.forename: Mariamma G
authors.initials: MG
authors.lastname: Joseph
authors.forename: Claire
authors.initials: C
authors.lastname: Temple
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005153:Facial Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D018327:Hutchinson's Melanotic Freckle / Q000188:drug therapy* / Q000601:surgery; D000077271:Imiquimod; D008297:Male; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod